Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients
Yunuo Zhang,Jingna Wu,Weiming Chen,Xinhong Liang
DOI: https://doi.org/10.2147/ijgm.s478000
IF: 2.145
2024-09-26
International Journal of General Medicine
Abstract:Yunuo Zhang, 1 Jingna Wu, 1 Weiming Chen, 2 Xinhong Liang 3 1 Department of Medical Oncology, Meizhou People's Hospital, Meizhou, People's Republic of China; 2 Data Center, Meizhou People's Hospital, Meizhou, People's Republic of China; 3 Radiology Department, Meizhou People's Hospital, Meizhou, People's Republic of China Correspondence: Xinhong Liang, Radiology Department, Meizhou People's Hospital, Meizhou, People's Republic of China, Email Objective: Immune inflammatory response are involved in the development and progression of cancer. However, there are still inconsistent research results on the value of peripheral blood inflammatory indicators for evaluating the efficacy of neoadjuvant therapy (NAT) in breast cancer. The purpose of this study was to investigate the relationship between pretreatment systemic immune inflammatory response index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and NAT efficacy in breast cancer. Methods: A retrospective analysis was performed on 326 patients with breast cancer who underwent NAT at Meizhou People's Hospital from November 2017 to October 2023. Clinicopathological data was collected, including gender, age, body mass index (BMI), hypertension, diabetes mellitus, family history of cancer, TNM stage, and the molecular subtypes of breast cancer. The optimal cutoff values of SII, SIRI, NLR, PLR, and LMR were calculated using receiver operating characteristic (ROC) curve, and the relationship between inflammatory indexes and other clinicopathological features and the efficacy of NAT was analyzed. Results: In this study, 162 (49.7%) breast cancer patients did not respond to NAT and 164 (50.3%) patients responded to NAT. The levels of SII ( p =0.002), SIRI ( p < 0.001), and NLR ( p =0.006) in patients who responded to NAT were significantly higher than those in patients who did not. When the efficacy of NAT was considered as the endpoint of SII, SIRI, and NLR, the critical value of the SII, SIRI, and NLR was 572.53 (under the ROC curve (AUC)=0.598), 0.745 (AUC=0.630), and 2.325 (AUC=0.588), respectively. Logistic regression analysis showed that a high SIRI level (≥ 0.745/< 0.745, OR: 2.447, 95% CI: 1.375– 4.357, p =0.002) was an independent factor associated with the efficacy of NAT in breast cancer patients. Conclusion: High SIRI levels (≥ 0.745) may be an independent factor associated with the efficacy of NAT in patients with breast cancer. Keywords: breast cancer, neoadjuvant therapy, systemic immune inflammatory response index, efficacy Breast cancer is a malignant tumor that occurs in the epithelial tissue of the breast, the great majority of which is women. 1 Breast cancer is a common malignant tumor in women, statistics in 2020 show that the global incidence of female breast cancer is 11.7%, with approximately 2.26 million new cases of breast cancer worldwide every year. Breast cancer has the highest incidence of malignant tumors in the world. 2 Breast cancer is classified into four molecular subgroups, luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) enriched (HER2+), and triple negative breast cancer (TNBC), based on the expression of hormone receptors (HR) (including estrogen receptor (ER) and progesterone receptor (PR)), HER2, and Ki67 (a proliferation index marker) in the patient's cancer tissue. 3 Luminal A subtype breast cancer was defined as ER positive (ER+), PR≥20%, HER2 negative (HER2-), Ki67<20%. Luminal B-like (HER2-) breast cancer was ER+, HER2-, and Ki67≥20%, PR<20%. Luminal B-like (HER2+) breast cancer was defined as ER+, HER2+, any Ki67 level and PR level. Luminal B-like (HER2-) and Luminal B-like (HER2+) are combined to form the Luminal B type. HER2+ subtype breast cancer was defined as HER2+, ER-, and PR-, and TNBC is defined as ER-, PR-, and HER2-. 4,5 Neoadjuvant therapy (NAT) is a preoperative systemic treatment for breast cancer patients without distant metastases and includes neoadjuvant endocrine therapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy. 6,7 The purpose of NAT is to reduce the tumor size, increase the chance of surgical resection, and increase the possibility of breast preservation surgery. 8,9 In addition, information about tumor sensitivity to drugs can be obtained during NAT, so as to guide subsequent therapy, and improve patient prognosis. 10 Assessment of response to NAT is critical for predicting survival and guiding subsequent treatment. The response to NAT of breast cancer patients includes both clinical an -Abstract Truncated-
medicine, general & internal